Connect with us

EU

#JunckerPlan supports Almirall's research into new skin disease treatments with €120 million European Investment Bank loan

SHARE:

Published

7 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Investment Bank is providing €120 million in financing under the Juncker Plan to Spanish pharmaceutical companyAlmirall to develop new medication for dermatological problems currently lacking effective treatment.

The financing will target research and development of therapies for patients with inflammatory dermatological diseases, selected cutaneous cancers and rare congenital disorders. Health and Food Safety Commissioner Vytenis Andriukaitis said: “The EU's dedication to improving availability and access to specialized care has been shown today. There can be no innovative solutions without investment, and so it is vital we continue to guarantee funding at EU-level to ensure companies can develop new medications for diseases which currently have no treatment or cure. Patients must be at the core of every R&D strategy, and so I very much welcome EIB's support in this field.''

A press release is available here. As of June 2019, the Juncker Plan has already mobilized €408.4 billion of additional investment, including €43.5bn in Spain. The Plan is currently supporting 952,000 small and medium businesses across Europe.

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending